While Ionis Pharmaceuticals Inc has underperformed by -1.05%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, IONS rose by 21.22%, with highs and lows ranging from $52.34 to $23.95, whereas the simple moving average jumped by 21.62% in the last 200 days.
On July 01, 2025, Barclays Upgraded Ionis Pharmaceuticals Inc (NASDAQ: IONS) to Overweight. A report published by H.C. Wainwright on April 07, 2025, Initiated its previous ‘Buy’ rating for IONS. Redburn Atlantic also rated IONS shares as ‘Neutral’, setting a target price of $39 on the company’s shares in an initiating report dated March 31, 2025. BMO Capital Markets August 02, 2024d the rating to Market Perform on August 02, 2024, and set its price target from $67 to $60. Leerink Partners July 24, 2024d its ‘Market Perform’ rating to ‘Outperform’ for IONS, as published in its report on July 24, 2024. Jefferies’s report from July 16, 2024 suggests a price prediction of $75 for IONS shares, giving the stock a ‘Buy’ rating. Bernstein also rated the stock as ‘Mkt Perform’.
Analysis of Ionis Pharmaceuticals Inc (IONS)
Further, the quarter-over-quarter increase in sales is 10.14%, showing a positive trend in the upcoming months.
Ionis Pharmaceuticals Inc’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of -118.53% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 9.62, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and IONS has an average volume of 1.71M. On a monthly basis, the volatility of the stock is set at 3.34%, whereas on a weekly basis, it is put at 2.95%, with a loss of -2.78% over the past seven days. Furthermore, long-term investors anticipate a median target price of $56.62, showing growth from the present price of $42.38, which can serve as yet another indication of whether IONS is worth investing in or should be passed over.
How Do You Analyze Ionis Pharmaceuticals Inc Shares?
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 2.44%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 104.18% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
IONS shares are owned by institutional investors to the tune of 104.18% at present.
